TRIB

Trinity Biotech plc Sponsored ADR (TRIB) | Rumor.io

Trinity Biotech

TRIB

Attention (50-day avg)0%

Attention rank (50-day avg)#4,681

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.55

Market capitalization5.5M

Earnings per share-60

Dividend yield (TTM)12.6%

Revenue (annual)43.8M

Net income (annual)-37.4M

Social

What share of all stock conversation is about TRIB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 28

$TRIB is at a new high of the day, with some traders speculating it may be a strong performer.
The stock's volume is increasing, and some traders are predicting it may break out or go parabolic.
$TRIB's management is expected to issue more shares, potentially diluting the stock's value, as the company is running out of money.

Generated by AI

Sentiment

Of the messages about TRIB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.76% -0.4
Bearish	—	—	—	10.24% +0.4

Bullish· Jun 23

Trinity Biotech has a large addressable market in diagnostics, with products targeting diabetes, infectious disease, and autoimmune markets.
The company has a significant short interest, with a short percentage of 1.29%, which could lead to a short squeeze.
Trinity Biotech has a new subsidiary focused on AI data center cooling and has secured a $25M financing commitment, which could be a catalyst for further growth.

Bearish· Jun 23

The company has issued millions of new shares through an ATM facility, potentially leading to significant dilution and a decrease in shareholder value.
A reverse stock split is anticipated, which could result in a substantial decline in the stock price.
The stock has been heavily shorted by the bookrunner, which may lead to a significant decline in the stock price when the shorts are covered.

Generated by AI

Topics

Of the messages about TRIB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	42.55%
Analysts	—	—	—	14.68%
Controversies	—	—	—	0.43%
Earnings	—	—	—	0.85%
Macro	—	—	—	22.13%
Technical Analysis	—	—	—	19.36%

Announcements· Jun 23

Trinity Biotech plc ($TRIB) launched Trinovium, a new subsidiary focused on advanced liquid cooling solutions for AI data centers, utilizing existing manufacturing capacity in the US and EU.
The data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033, with Trinity Biotech positioning itself as an emerging AI infrastructure enabler through this initiative.
Trinovium aims to provide direct-to-chip cooling fluids with ultra-high-purity and highly stable aqueous chemistry, as well as corrosion inhibitors for coolant system protection, capitalizing on the industry transition from standard air-cooling infrastructure to direct-to-chip liquid cooling.

Technical Analysis· Dec 23

$TRIB has rejected the day's high at $1.75, a price level considered pivotal for analysis and trading decisions.
A potential dip to $1.50 could trigger a move to $1.60, with $1.75 as a possible next target.
$TRIB has shown strength, with volume holding up despite a price dip, and a key reversal level at $1.3 that must be defended to avoid a bearish scenario.

Generated by AI

Community

Of the messages about TRIB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	32.31%
Newcomers	—	—	—	67.69%

Regulars· Aug 20

The FDA has set back Trinity Biotech's PRISM mid-day movers, and the company is facing pressure from a convertible note.
Trinity Biotech has received regulatory approval to commence manufacturing of its flagship Rapid HIV test, facilitating a strategic and financial performance transformation.
The stock price of Trinity Biotech has been volatile, with sharp drops triggered by UltraShort signals and subsequent clean 20% pops for UltraBuyers who caught dips at specific levels.

Newcomers· Aug 20

Newcomers are looking for short squeeze opportunities in $TRIB, with some mentioning potential profit targets.
Several users are identifying $TRIB as a potential gapper, with some even taking trade ideas based on its performance.
There is a notable news event for $TRIB, with Trinity Biotech plc granted approval for offshore manufacturing of the TrinScreen HIV test.

Generated by AI

The global point-of-care diagnostics market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at an 8.8% CAGR. Growth is driven by demand for rapid, accurate and decentralized testing, alongside advances in molecular diagnostics, microfluidics, multiplex assays and portable analyzers. Biochemistry holds the largest technology share, while molecular diagnostics and infectious disease testing are set for strong growth. Clinical laboratories lead by end user, and Nor

14d agoYahoo Finance

Trinity Biotech Files 2025 Annual Report and AGM Materials with SEC

Tipranks Press Release.

21d agoThe Globe and Mail

Trinity Biotech expands PrePsia patent portfolio to nine patents

1mo agoInvesting.com

Trinity Biotech’s Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure

- Collaboration with leading hyperscale data center company will support Trinovium's technical and commercial readiness through development of cooling technologies for next-generation AI and modular data center infrastructure - Data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 20331 DUBLIN and WILSONVILLE, Ore., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ: TRIB) today announced that Trinovium, a subsidiary focused on advanced liqui

1mo agoYahoo Finance

Trinity Biotech's Trinovium, Echelon to Collaborate on Data Center Liquid Cooling

1mo agoYahoo Finance

Trinity Biotech secures $7m from Perceptive Advisors

1mo agoInvesting.com

Also Discussed

Investors talking about TRIB also mention

#	Name	Attention
1	BSLK - Bolt Projects Holdings, Inc.	——
2	BIO-key International, Inc.BKYI	0.08%+0.08
3	Expion360 Inc.XPON	0%0
4	Sonoma Pharmaceuticals Inc.SNOA	0%0
5	Biomerica Inc.BMRA	0%0
6	TCON - TRACON Pharmaceuticals, Inc.	——
7	AIM ImmunoTech Inc.AIM	0%0
8	BIOC - Biocept, Inc.	——
9	RGLS - Regulus Therapeutics Inc.	——
10	Can-Fite BioPharma Ltd. ADRCANF	0%0

Trinity Biotech plc Sponsored ADR

Healthcare
Medical Devices

Trinity Biotech plc Sponsored ADR represents shares in Trinity Biotech plc, an Ireland-based commercial-stage biotechnology company headquartered in Bray. The company specializes in the development, acquisition, manufacture, and marketing of diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. Its offerings include test kits that detect infectious diseases such as HIV through products like Uni-Gold and TrinScreen, sexually transmitted diseases, autoimmune disorders, haemoglobin disorders, and support diabetes management via solutions like the Premier Hb9210 HbA1c system for monitoring blood glucose levels. Trinity Biotech also provides raw materials to the life sciences industry and has entered the wearable biosensor space for human diagnostics. Operating through segments in the Americas and Rest of World, it sells diagnostic systems, reagents, and instrumentation directly in key markets like the United States and Brazil, and via a global network of distributors and partners reaching over 100 countries. Manufacturing facilities span Ireland, the United States, and Brazil, enabling production of high-volume point-of-care tests and specialized laboratory products.

Website

Location

IDA Business Park

Bray, A98 H5C8

Ireland

Social

What share of all stock conversation is about TRIB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 28

$TRIB is at a new high of the day, with some traders speculating it may be a strong performer.
The stock's volume is increasing, and some traders are predicting it may break out or go parabolic.
$TRIB's management is expected to issue more shares, potentially diluting the stock's value, as the company is running out of money.

Generated by AI

Sentiment

Of the messages about TRIB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.76% -0.4
Bearish	—	—	—	10.24% +0.4

Bullish· Jun 23

Trinity Biotech has a large addressable market in diagnostics, with products targeting diabetes, infectious disease, and autoimmune markets.
The company has a significant short interest, with a short percentage of 1.29%, which could lead to a short squeeze.
Trinity Biotech has a new subsidiary focused on AI data center cooling and has secured a $25M financing commitment, which could be a catalyst for further growth.

Bearish· Jun 23

The company has issued millions of new shares through an ATM facility, potentially leading to significant dilution and a decrease in shareholder value.
A reverse stock split is anticipated, which could result in a substantial decline in the stock price.
The stock has been heavily shorted by the bookrunner, which may lead to a significant decline in the stock price when the shorts are covered.

Generated by AI

Topics

Of the messages about TRIB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	42.55%
Analysts	—	—	—	14.68%
Controversies	—	—	—	0.43%
Earnings	—	—	—	0.85%
Macro	—	—	—	22.13%
Technical Analysis	—	—	—	19.36%

Announcements· Jun 23

Trinity Biotech plc ($TRIB) launched Trinovium, a new subsidiary focused on advanced liquid cooling solutions for AI data centers, utilizing existing manufacturing capacity in the US and EU.
The data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033, with Trinity Biotech positioning itself as an emerging AI infrastructure enabler through this initiative.
Trinovium aims to provide direct-to-chip cooling fluids with ultra-high-purity and highly stable aqueous chemistry, as well as corrosion inhibitors for coolant system protection, capitalizing on the industry transition from standard air-cooling infrastructure to direct-to-chip liquid cooling.

Technical Analysis· Dec 23

$TRIB has rejected the day's high at $1.75, a price level considered pivotal for analysis and trading decisions.
A potential dip to $1.50 could trigger a move to $1.60, with $1.75 as a possible next target.
$TRIB has shown strength, with volume holding up despite a price dip, and a key reversal level at $1.3 that must be defended to avoid a bearish scenario.

Generated by AI

Community

Of the messages about TRIB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	32.31%
Newcomers	—	—	—	67.69%

Regulars· Aug 20

The FDA has set back Trinity Biotech's PRISM mid-day movers, and the company is facing pressure from a convertible note.
Trinity Biotech has received regulatory approval to commence manufacturing of its flagship Rapid HIV test, facilitating a strategic and financial performance transformation.
The stock price of Trinity Biotech has been volatile, with sharp drops triggered by UltraShort signals and subsequent clean 20% pops for UltraBuyers who caught dips at specific levels.

Newcomers· Aug 20

Newcomers are looking for short squeeze opportunities in $TRIB, with some mentioning potential profit targets.
Several users are identifying $TRIB as a potential gapper, with some even taking trade ideas based on its performance.
There is a notable news event for $TRIB, with Trinity Biotech plc granted approval for offshore manufacturing of the TrinScreen HIV test.

Generated by AI

Trinity Biotech

Social

Jul 28

Bullish· Jun 23

Bearish· Jun 23

Announcements· Jun 23

Technical Analysis· Dec 23

Regulars· Aug 20

Newcomers· Aug 20

Point of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key Players

Trinity Biotech Files 2025 Annual Report and AGM Materials with SEC

Trinity Biotech expands PrePsia patent portfolio to nine patents

Trinity Biotech’s Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure

Trinity Biotech's Trinovium, Echelon to Collaborate on Data Center Liquid Cooling

Trinity Biotech secures $7m from Perceptive Advisors

Also Discussed

Trinity Biotech plc Sponsored ADR

Company Information

Location

Point of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key Players

Trinity Biotech Files 2025 Annual Report and AGM Materials with SEC

Trinity Biotech expands PrePsia patent portfolio to nine patents

Trinity Biotech’s Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure

Trinity Biotech's Trinovium, Echelon to Collaborate on Data Center Liquid Cooling

Trinity Biotech secures $7m from Perceptive Advisors

Also Discussed

Social

Jul 28

Bullish· Jun 23

Bearish· Jun 23

Announcements· Jun 23

Technical Analysis· Dec 23

Regulars· Aug 20

Newcomers· Aug 20